Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news: NKA +207.6% (to be acquired by Brookfield Infrastructure (BIP) for ~$912 mln), SPF +2.9% (Standard Pacific and Ryland Group (RYL) announce merger of equals), RYL +1.2%
Other news: AXPW +56.7% (signs a binding Letter of Intent, for a technology development and licensing program with LCB International), RDHL +29.8% (meets primary endpoint in its Phase III Study of RHB-105 to treat H. pylori Infection), AMCN +14% (to sell 75% of the equity interest in its Advertising Business for RMB 2.1 bln), NURO +8.5% (announced the full commercial launch of Quell, the company's over-the-counter chronic pain relief device), BLRX +8.4% (positive safety and efficacy results for lead oncology candidate BL-8040), BLUE +5.9% (reports reports new data from HGB-205 study), PTBI +5.9% (adds another adeno-associated virus gene therapy program to its product pipeline), WEC +4% (discloses approval for its acquisition of Integrys Energy Group (TEG) by the Minnesota Public Utilities Commission), TRIV +3.9% (FDA has approved the Ovation iX Iliac Stent Graft for the Ovation Prime Abdominal Stent Graft System), ZGNX +3.1% (Zogenix and Valeant Pharma (VRX) terminate co-promotion agreement for Migranal ), MNKD +3% (cont strength from Friday), GALE+2.1% (Phase 2 pilot study demonstrated an Overall Response Rate of 78%), CTIC +2% (reports Tosedostat in combination with low dose Cytarabine achieves primary endpoint in Phase 2 Study), GERN +1.2% (confirms orphan designation for its imetelstat for the treatment of myelofibrosis), RLD +1.1% (Jurassic World in 3D accounted for ~48% of ~$204.6 mln in domestic opening weekend), KPTI +0.8% (positive clinical data for its lead product candidate)
Analyst comments: IDRA +5.9% (initiated with a Overweight at JP Morgan), SNSS +2.3% (target raised to $5.50 at ROTH Capital), PBI +1.2% (initiated with a Buy at Ladenburg Thalmann
)
In reaction to strong earnings/guidance: N/A.
M&A news: NKA +207.6% (to be acquired by Brookfield Infrastructure (BIP) for ~$912 mln), SPF +2.9% (Standard Pacific and Ryland Group (RYL) announce merger of equals), RYL +1.2%
Other news: AXPW +56.7% (signs a binding Letter of Intent, for a technology development and licensing program with LCB International), RDHL +29.8% (meets primary endpoint in its Phase III Study of RHB-105 to treat H. pylori Infection), AMCN +14% (to sell 75% of the equity interest in its Advertising Business for RMB 2.1 bln), NURO +8.5% (announced the full commercial launch of Quell, the company's over-the-counter chronic pain relief device), BLRX +8.4% (positive safety and efficacy results for lead oncology candidate BL-8040), BLUE +5.9% (reports reports new data from HGB-205 study), PTBI +5.9% (adds another adeno-associated virus gene therapy program to its product pipeline), WEC +4% (discloses approval for its acquisition of Integrys Energy Group (TEG) by the Minnesota Public Utilities Commission), TRIV +3.9% (FDA has approved the Ovation iX Iliac Stent Graft for the Ovation Prime Abdominal Stent Graft System), ZGNX +3.1% (Zogenix and Valeant Pharma (VRX) terminate co-promotion agreement for Migranal ), MNKD +3% (cont strength from Friday), GALE+2.1% (Phase 2 pilot study demonstrated an Overall Response Rate of 78%), CTIC +2% (reports Tosedostat in combination with low dose Cytarabine achieves primary endpoint in Phase 2 Study), GERN +1.2% (confirms orphan designation for its imetelstat for the treatment of myelofibrosis), RLD +1.1% (Jurassic World in 3D accounted for ~48% of ~$204.6 mln in domestic opening weekend), KPTI +0.8% (positive clinical data for its lead product candidate)
Analyst comments: IDRA +5.9% (initiated with a Overweight at JP Morgan), SNSS +2.3% (target raised to $5.50 at ROTH Capital), PBI +1.2% (initiated with a Buy at Ladenburg Thalmann
)